Quantitative structure-activity relationship (QSAR) analysis to predict drug-drug interactions of ABC transporter ABCG2

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 6, 2012, Pages 505-514

  Ishikawa, T ^a   Hirano, H ^a   Saito, H ^a,b   Sano, K ^c   Ikegami, Y ^c   Yamaotsu, N ^d   Hirono, S ^d  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY   (Japan)

Author keywords

ABC transporter; ABCG2; Camptothecin; Gefitinb; Irinotecan; Multidrug resistance; QSAR analysis

Indexed keywords

7 ETHYLCAMPTOTHECIN; ADENOSINE TRIPHOSPHATE; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; DIFLOMOTECAN; FIRTECAN; GEFITINIB; HEMATOPORPHYRIN; IRINOTECAN; METHOTREXATE; NOVOBIOCIN; PHEOPHORBIDE; PRAZOSIN; QUERCETIN; SN 343; SN 348; SN 349; SN 351; SN 352; SN 353; SN 355; SN 364; SN 392; SN 397; SN 398; SN 443; SN 444; TACROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG; URIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CODING ALGORITHM; DIARRHEA; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG TRANSPORT; EXON; GENETIC ASSOCIATION; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HYDROLYSIS; IC 50; LUNG CARCINOMA; NUCLEOTIDE TRANSPORT; NUCLEOTIDE TRAPPING; PREDICTION; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SINGLE NUCLEOTIDE POLYMORPHISM; URIC ACID BLOOD LEVEL;

EID: 84861139188     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712800493825     Document Type: Article

References (37)

1. Hansch, C.; Leo, A. Substituent Constants for Correlation Analysis in Chemistry and Biology. John Wiley & Sons, New York, 1979.
2. Selassie, C.D. In: Burger's Medicinal Chemistry and Drug Discovery. Sixth Edition, Abraham, D.J., Ed.; John Wiley & Sons, New York, 2003; Vol. 1, pp. 1-48
3. Giacomini, K.M.; Huang, S.M.; Tweedie, D.J.; Benet, L.Z.; Brouwer, K.L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K.M.; Hoffmaster, K.A.; Ishikawa, T.; Keppler, D.; Kim, R.B.; Lee, C.A.; Niemi, M.; Polli, J.W.; Sugiyama, Y.; Swaan, P.W.; Ware, J.A.; Wright, S.H.; Yee, S.W.; Zamek-Gliszczynski, M.J.; Zhang, L. Membrane Transporters in Drug Development: Report from the FDA Critical Path Initiative-Sponsored Workshop. Nature Review Drug Discovery, 2010, 9, 215-236.
4. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15665-15670.
5. Vlaming, M.L.; Lagas, J.S.; Schinkel, A.H. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv. Drug Deliv. Rev. 2009, 61, 14-25.
6. Wakabayashi, K.; Nakagawa, H.; Tamura, A.; Koshiba, S.; Hoshijima, K.; Komada, M.; Ishikawa, T. Intramolecular disulfide bond is a critical checkpoint determining degradative fates of ABC transporter ABCG2 protein. J. Biol. Chem., 2007, 282, 27841-27846.
7. Wakabayashi, K.; Tamura, A.; Saito, H.; Onishi, Y.; Ishikawa, T. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab. Rev., 2006, 38, 371-391.
8. Wakabayashi-Nakao, K.; Tamura, A.; Furukawa, T.; Nakagawa, H.; Ishikawa, T. Quality control of human ABCG2 protein in the endoplasmeic reticulm: ubiquitination and proteasomal degradation. Adv. Drug. Deliv. Rev., 2009, 61, 66-72.
9. Sauna, Z.E.; Ambudkar, S.V. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc. Natl. Acad. Sci. USA, 2000, 97, 2515-2520.
10. Sauna, Z.E.; Kim, I.W.; Nandigama, K.; Kopp, S.; Chiba, P.; Ambudkar, S.V. Catalytic cycle of ATP hydrolysis by Pglycoprotein: evidence for formation of the E-S reaction intermediate with ATP-g-S, a nonhydrolyzaable analogue of ATP. Biochemistry, 2007, 46, 13787-13799.
11. Özvegy, C.; Váradi, A.; Sarkadi, B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. J. Biol. Chem., 2002, 277, 47980-47990.
12. Saito, H.; Hirano, H.; Nakagawa, H.; Fukami, T.; Oosumi, K.; Murakami, K.; Kimura, H.; Kouchi, T.; Konomi, M.; Tao, E.; Tsujikawa, N.; Tarui, S.; Nagakura, M.; Osumi, M.; Ishikawa, T. A new strategy of high-speed screening and quantitative structureactivity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J. Pharmacol. Exp. Ther., 2006, 317, 1114-1124.
13. Volk, E. L,; Farley, K.M.; Wu, Y.; Li, F.; Robey, R.W.; Schneider, E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 2002, 62, 5035-5040.
14. Chen, Z.S.; Robey, R.W.; Belinsky, M.G.; Shchaveleva, I.; Ren, X.Q.; Sugimoto, Y.; Ross, D.D.; Bates, S.E.; Kruh, G.D. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003, 63, 4048-405.
15. Mitomo, H.; Kato, R.; Ito A, Kasamatsu, S.; Ikegami, Y/; Kii, I.; Kudo, A.; Kobatake, E.; Sumino, Y.; Ishikawa, T. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem. J., 2003, 373, 767-774.
16. Ishikawa T, Sakurai A, Kanamori Y, Nagakura M, Hirano H, Takarada Y, Yamada K, Fukushima K and Kitajima M. High-speed screening of human ATP-binding cassette transporter function and genetic polymorphisms: new strategies in pharmacogenomics. Methods Enzymol., 2005, 400, 485-510.
17. Danceyand, J.; Sausville, E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov., 2003, 2, 296-313.
18. Noble, M.E., Endicott, J.A. and Johnson, L.N. Protein kinase inhibitors: insights into drug design from structure. Science, 2004, 303, 1800-1805.
19. Ozvegy-Laczka, C.; Cserepes, J.; Elkind, N.B.; Sarkadi, B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist. Updat., 2005, 8, 15-26.
20. Yoshikawa, M.; Ikegami, Y.; Hayasaka, S.; Ishii, K.; Ito, A.; Sano, K.; Suzuki, T.; Togawa, T.; Yoshida, H.; Soda, H.; Oka, M.; Kohno, S.; Sawada, S.; Ishikawa, T.; Tanabe, S. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int. J. Cancer, 2004, 110, 921-927.
21. Nakagawa, H.; Tamura, A.; Wakabayashi, K.; Hoshijima, K.; Komada, M.; Yoshida, T.; Kometani, S.; Matsubara, T.; Mikuriya, K.; Ishikawa, T. Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. Biochemical J., 2008, 411, 623-631.
22. Furukawa, T.; Wakabayashi, K.; Tamura, A.; Nakagawa, H.; Morishima, Y.; Osawa, Y.; Ishikawa, T. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteosomal degradations. Pharm Res., 2009, 26, 469-479.
23. Sparreboom, A.; Loos, W.J.; Burger, H.; Sissung, T.M.; Verweij, J.; Figg, W.D.; Nooter, K.; Gelderblom, H. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther., 2005, 4, 650-658.
24. Sparreboom, A.; Gelderblom, H.; Marsh, S.,; Ahluwalia, R.; Obach, R.; Principe, P.; Twelves, C.; Verweij, J.; McLeod, H.L. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin. Pharmacol. Ther., 2004, 1, 38-44.
25. Honjo, Y.; Morisaki, K.; Huff, L.M.; Robey, R.W.; Hung, J.; Dean, M.; Bates, S.E. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol. Ther., 2002, 6: 696-702.
26. Warren, R.B.; Smith, R.L.; Campalani, E.; Eyre, S.; Smith, C.H.; Barker, J.N.W.N.; Worthington, J.; Griffith, C.E.M. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J. Invest Dermatol., 2008, 128,1925-1929.
27. Yamasaki, Y.; Ieiri, I.; Kusuhara, H.; Sasaki, T.; Kimura, M.; Tabuchi, H.; Ando, Y.; Irie, S.; Ware, J.; Nakai, Y.; Higuchi, S.; Sugiyama, Y. Pharmacogenetic characterization of sulfasalazine diposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms. Clin. Pharmacol. Ther., 2008, 84, 95-103.
28. Cusatis, G.; Sparreboom, A. Pharmacogenomic importance of ABCG2. Pharmacogenomics, 2008, 9, 1005-1009.
29. Cusatis, G.; Gregorc, V.; Li, J.; Spreafico, A.; Ingersoll, R.G.; Verweij, J.; Ludovini, V.; Villa, E.; Hidalgo, M.; Sparreboom, A.; Baker, S.D. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib, J. Natl. Cancer Inst. 2006, 98, 1739-1742.
30. Stark, K.; Reinhard, W.; Grassi, M.; Erdmann, J.; Schunkert, H.; Illig, T.; Hengstenberg, C. Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS ONE, 2009, 4, e7729.
31. Woodward, O.; Köttgen, A.; Coresh, J.; Boerwinkle, E.; Guggino, W.B.; Köttgen, M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. USA., 2009, 106, 10338-10342.
32. Matsuo, H.; Takada, T.; Ichida, K.; Nakamura, T.; Nakayama, A.; Ikebuchi, Y.; Ito, K.; Kusanagi, Y.; Chiba, T.; Tadokoro, S.; Takada, Y.; Oikawa, Y.; Inoue, H.; Suzuki, K.; Okada, R.; Nishiyama, J.; Domoto, H.; Watanabe, S.; Fujita, M.; Morimoto, Y.; Naito, M.; Nishio, K.; Hishida, A.; Wakai, K.; Asai, Y.; Niwa, K.; Kamakura, K.; Nonoyama, S.; Sakurai, Y.; Hosoya, T.; Kanai, Y.; Suzuki, H.; Hamajima, N.; Shinomiya, N. Common defects of ABCG2, a high-capacity urate exporter, cause gout. A functionbased genetic analysis in a Japanese population. Science Trans. Med., 2009, 1, 5ra11.
33. Nicolle, E.; Boumendjel, A.; Macalou, S.; Genoux, E.; Ahmed-Belkacem, A.; Carrupt, P.A.; Di Pietro, A. QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv. Drug Deliv. Rev., 2008, 61, 34-46.
34. Nicolle, E.; Boccard, J.; Guilet, D.; Dijoux-Franca, M.G.; Zelefac, F.; Macalou, S.; Grosselin, J.; Schmidt, J.; Carrupt, P.A.; Di Pietro, A.; Boumendjel. A. Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. Eur. J. Pharm. Sci., 2009, 38, 39-46.
35. Tamaki, H.; Satoh, H.; Hori, S.; Ohtani, H.; Sawada Y. Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab. Pharmacokinet. 2010, 25, 170-179.
36. Gandhi, Y.A.; Morris, M.E. Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (BCRP). AAPS J. 2009, 11, 541-552.
37. Pick, A.; Muller, H.; Wiese, M. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg. Medicin. Chem., 2008, 16, 8224-8236.